Moderna, Inc. (MRNA)
Moderna develops messenger-RNA vaccines and therapeutics, including its COVID-19 vaccine.
Health Care stock comparison
MRNA vs TECH: which business are you actually underwriting?
Compare Moderna, Inc. with Bio-Techne Corporation using their business models, SEC classifications, fiscal calendars, current primary filings, and the research questions that matter. This is a thesis framework—not a price target or automatic winner.
- Sector
- Health
- Industry
- Same SIC
- Shared themes
- 1
- Updated
- 2026-02-20
MRNA vs TECH: quick comparison
| Company fact | MRNA | TECH |
|---|---|---|
| Company | Moderna, Inc. | Bio-Techne Corporation |
| Exchange | NASDAQ | NASDAQ |
| Headquarters | Not recorded | Not recorded |
| Founded | Not recorded | Not recorded |
| SEC industry | Biological Products, (No Diagnostic Substances) | Biological Products, (No Diagnostic Substances) |
| Fiscal year-end | December 31 | June 30 |
| Latest annual filing | 10-K · 2026-02-20 | 10-K · 2025-08-22 |
How the businesses differ
Bio-Techne Corporation (TECH)
Bio-Techne makes reagents, proteins, and instruments used in biological research and diagnostics.
The useful starting point is not which ticker has performed better. It is whether the two companies convert the same economic forces into revenue and cash flow in the same way. MRNA is classified by the SEC as Biological Products, (No Diagnostic Substances), while TECH is classified as Biological Products, (No Diagnostic Substances). The matching industry code strengthens the peer comparison, although product mix can still differ materially.
Which thesis does each company fit?
Use the distinction below to decide which filing deserves deeper work. It is a research routing rule, not a recommendation or prediction.
Study MRNA when…
- Drug approvals and clinical-trial readouts
- Medicare and drug-pricing policy
- Demographics and an aging population
- GLP-1 and obesity-drug demand
Study TECH when…
- Drug approvals and clinical-trial readouts
- Medicare and drug-pricing policy
- Demographics and an aging population
- GLP-1 and obesity-drug demand
Shared research themes
US markets
SEC filing comparison and disclosure evidence
Start with primary filings because fiscal calendars and accounting presentation can make superficially similar quarters incomparable.MRNA's fiscal year ends December 31, while TECH's ends June 30. Normalize the reporting periods before comparing growth, margins, capital intensity, or guidance.
The current verified House Clerk snapshot contains 0matched transaction rows for MRNAand 0 for TECH. These delayed, range-based disclosures can identify a filing to inspect; they do not establish motive, conviction, or a real-time trading signal.
MRNA primary filings
TECH primary filings
What this comparison cannot tell you
This page does not contain licensed live prices, a valuation model, earnings estimates, portfolio constraints, or a forecast of future returns. SEC classifications can be broad, company descriptions can lag strategic change, and the latest annual filing may predate a material acquisition or divestiture. Read subsequent quarterly and current reports before making a decision.
A stronger business is not automatically the better stock. Starting valuation, expectations, capital structure, cyclicality, dilution, and the probability of each thesis determine the investment outcome. Use this comparison to frame the work, then verify the numbers in the linked filings and current company disclosures.
More comparisons involving MRNA or TECH
MRNA vs TECH FAQs
Are MRNA and TECH direct competitors?
Moderna, Inc. and Bio-Techne Corporation share the SEC industry classification “Biological Products, (No Diagnostic Substances).” That makes the operating comparison relevant, but it does not prove that every product, customer, or revenue stream competes directly.
Which is better, MRNA or TECH?
There is no context-free winner. Compare the operating exposures, filing evidence, valuation, balance sheet, and risks against the specific thesis you are testing. This page deliberately does not turn a static profile into a buy or sell recommendation.
Does this MRNA vs TECH comparison include live prices?
No. Yield Theory does not republish unlicensed real-time market data. Use a regulated broker or licensed quote provider for current prices, then use the primary filings here to test the business thesis.
Where does the company information come from?
Company classifications, fiscal year-ends, and filing links come from the SEC EDGAR submissions API snapshot refreshed 2026-08-10. Business summaries and research themes are maintained by Yield Theory.
Data snapshot: SEC EDGAR submissions API, refreshed 2026-08-10. Independent educational research; not investment advice.
Go beyond MRNA vs TECH.
Yield Theory connects filings, capital flows, catalysts, and risks into an investable research process.
$15/mo or $150/yr · cancel future renewals anytime · sources included